Form 8-K - Current report:
SEC Accession No. 0001628280-25-023478
Filing Date
2025-05-08
Accepted
2025-05-08 08:03:30
Documents
15
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mnlo-20250508.htm   iXBRL 8-K 25044
2 EX-99.1 vyne-20250508q12025exx991.htm EX-99.1 91842
6 imagea.jpg GRAPHIC 16124
  Complete submission text file 0001628280-25-023478.txt   273986

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mnlo-20250508.xsd EX-101.SCH 1909
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mnlo-20250508_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mnlo-20250508_pre.xml EX-101.PRE 12621
17 EXTRACTED XBRL INSTANCE DOCUMENT mnlo-20250508_htm.xml XML 2720
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 25923972
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)